SK283067B6 - Spôsob výroby epoxidu - Google Patents

Spôsob výroby epoxidu Download PDF

Info

Publication number
SK283067B6
SK283067B6 SK1122-96A SK112296A SK283067B6 SK 283067 B6 SK283067 B6 SK 283067B6 SK 112296 A SK112296 A SK 112296A SK 283067 B6 SK283067 B6 SK 283067B6
Authority
SK
Slovakia
Prior art keywords
formula
solution
epoxide
equivalent
allyl
Prior art date
Application number
SK1122-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK112296A3 (en
Inventor
David Askin
Kan K. Eng
Peter E. Maligres
Paul J. Reider
Kai Rossen
Ralph P. Volante
Veena Upadhyay
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22764868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK283067(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of SK112296A3 publication Critical patent/SK112296A3/sk
Publication of SK283067B6 publication Critical patent/SK283067B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1122-96A 1994-03-04 1995-02-27 Spôsob výroby epoxidu SK283067B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20607494A 1994-03-04 1994-03-04
PCT/US1995/002347 WO1995023797A1 (fr) 1994-03-04 1995-02-27 Procede de fabrication d'un epoxyde

Publications (2)

Publication Number Publication Date
SK112296A3 SK112296A3 (en) 1997-02-05
SK283067B6 true SK283067B6 (sk) 2003-02-04

Family

ID=22764868

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1122-96A SK283067B6 (sk) 1994-03-04 1995-02-27 Spôsob výroby epoxidu

Country Status (25)

Country Link
EP (1) EP0748319B1 (fr)
JP (1) JP3871705B2 (fr)
KR (1) KR100387741B1 (fr)
CN (1) CN1066728C (fr)
AT (1) ATE210662T1 (fr)
AU (1) AU690231B2 (fr)
BR (1) BR9506977A (fr)
CA (1) CA2183976C (fr)
CZ (1) CZ291816B6 (fr)
DE (1) DE69524578T2 (fr)
DK (1) DK0748319T3 (fr)
ES (1) ES2167419T3 (fr)
FI (1) FI120259B (fr)
HR (1) HRP950096B1 (fr)
HU (1) HU222750B1 (fr)
MX (1) MX9603871A (fr)
NZ (1) NZ281866A (fr)
PT (1) PT748319E (fr)
RO (1) RO117696B1 (fr)
RU (1) RU2137769C1 (fr)
SK (1) SK283067B6 (fr)
TW (1) TW380137B (fr)
UA (1) UA45968C2 (fr)
WO (1) WO1995023797A1 (fr)
YU (1) YU49010B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728840A (en) * 1994-03-04 1998-03-17 Merck & Co., Inc. Process for making an epoxide
TW415948B (en) * 1995-10-30 2000-12-21 Merck & Co Inc Process for synthesizing epoxide and halohydrin
US5981759A (en) * 1997-06-20 1999-11-09 Merck & Co., Inc. Process for indinavir intermediate
PT2623113T (pt) 2005-11-09 2017-07-14 Onyx Therapeutics Inc Compostos para inibição de enzimas
SI2041158T1 (sl) 2006-06-19 2013-09-30 Onyx Therapeutics, Inc. Peptidni epoksiketoni za inhibicijo proteasomov
TWI501773B (zh) 2007-10-04 2015-10-01 Onyx Therapeutics Inc 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
MX2012010017A (es) 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
CN103025730A (zh) * 2010-04-30 2013-04-03 印第安纳大学研究及科技有限公司 制备利奈唑胺的方法
WO2014011695A2 (fr) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique
CN104692987B (zh) * 2015-01-22 2017-05-17 北京大学 卤代醇及其衍生物的廉价高效合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072237A1 (fr) * 1991-07-02 1993-01-03 Merck & Co., Inc. Production stereoselective de composes hydroxyamide obtenus a partir d'–-aminoepoxydes chiraux
CA2081970C (fr) * 1991-11-08 1997-07-08 Joseph P. Vacca Utilisation d'agents inhibant la protease du vih pour le traitement du sida

Also Published As

Publication number Publication date
DK0748319T3 (da) 2002-03-18
ATE210662T1 (de) 2001-12-15
FI963452A (fi) 1996-09-03
CA2183976C (fr) 2005-02-01
FI120259B (fi) 2009-08-31
UA45968C2 (uk) 2002-05-15
EP0748319B1 (fr) 2001-12-12
BR9506977A (pt) 1997-09-02
SK112296A3 (en) 1997-02-05
RU2137769C1 (ru) 1999-09-20
DE69524578T2 (de) 2002-07-18
ES2167419T3 (es) 2002-05-16
CZ254396A3 (en) 1997-01-15
YU49010B (sh) 2003-04-30
HU9602412D0 (en) 1996-11-28
RO117696B1 (ro) 2002-06-28
WO1995023797A1 (fr) 1995-09-08
HRP950096A2 (en) 1997-06-30
CN1066728C (zh) 2001-06-06
HUT75611A (en) 1997-05-28
CN1146768A (zh) 1997-04-02
EP0748319A1 (fr) 1996-12-18
AU690231B2 (en) 1998-04-23
MX9603871A (es) 1997-07-31
YU14595A (sh) 1997-12-05
FI963452A0 (fi) 1996-09-03
PT748319E (pt) 2002-05-31
CA2183976A1 (fr) 1995-09-08
HRP950096B1 (en) 2002-06-30
JPH09509929A (ja) 1997-10-07
JP3871705B2 (ja) 2007-01-24
CZ291816B6 (cs) 2003-06-18
KR100387741B1 (ko) 2003-10-04
KR970701714A (ko) 1997-04-12
AU1882895A (en) 1995-09-18
NZ281866A (en) 1998-05-27
DE69524578D1 (de) 2002-01-24
HU222750B1 (hu) 2003-09-29
TW380137B (en) 2000-01-21

Similar Documents

Publication Publication Date Title
US6605732B1 (en) Clean, high-yield preparation of S,S and R,S amino acid isosteres
SK283067B6 (sk) Spôsob výroby epoxidu
TWI438188B (zh) 用於合成醫藥品之中間化合物的製造方法
RU2135482C1 (ru) Способ рацемизации оптически чистого или обогащенного пиперазин-2- трет.бутилкарбоксамидного субстрата и рацемический 2-трет-бутилкарбоксамид-4-(3- пиколил)пиперазин
EP0708763B1 (fr) Procede de preparation d'inhibiteurs de protease de vih
RU2125561C1 (ru) Промежуточные соединения для синтеза ингибиторов вич-протеаз и способы их получения
US5728840A (en) Process for making an epoxide
CZ266196A3 (cs) Regioselektivní způsob výroby cis-1-amino-2-indanolu
SK115096A3 (en) Regiospecific process to make cis-1-amino-2-alkanols
EP3773584A1 (fr) Procédés de préparation de composés tricycliques contenant de la pyridinone substituée
EP3986867B1 (fr) Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1h)-yl]éthénone
CA2167183C (fr) Methode pour l'obtention d'inhibiteurs de la protease du vih
JPH09255679A (ja) ジアザビシクロ［３．３．１］ノナン誘導体の製造方法

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20100429

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130227